Clinical Genitourinary Cancer

Aims & Scope

Clinical Genitourinary Cancer is a peer-reviewed journal that publishes original articles describing various aspects of clinical and translational research in genitourinary cancers.

Clinical Genitourinary Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of genitourinary cancers.

The main emphasis is on recent scientific developments in all areas related to genitourinary malignancies.

Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	2.7
2024	2.30

SJR (SCImago Journal Rank)

Year	Value
2024	1.130

Quartile

Year	Value
2024	Q1

h-index

Year	Value
2024	59

Journal Rank

Year	Value
2024	3946

Journal Citation Indicator

Year	Value
2024	1209

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Salvage Stereotactic Body Radiotherapy for Patients With Limited Prostate Cancer Metastases: Deferring Androgen Deprivation Therapy

  Citation: 159

  Authors: Patrick, Gert, Louke, Bieke, Valérie, Nicolaas, Karel, Geert, Philippe, Piet

• Potential Histologic and Molecular Predictors of Response to Temsirolimus in Patients with Advanced Renal Cell Carcinoma

  Citation: 151

  Authors: Daniel, Sabina, Sandra, Meredith, Apryle, Mauro, Amanda, Adam, Lucy, David, Eric, Michael

• Results of a Prospective Phase 2 Pilot Trial of 177Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression

  Citation: 149

  Authors: Louise, Megan, Bao, Kathy, Peter, Lalith, Richard, Ashley, Lisa, Alex, Kate, Craig, Charlotte, Phillip, Anthony M.

• Trends in Renal-Cell Carcinoma Incidence and Mortality in the United States in the Last 2 Decades: A SEER-Based Study

  Citation: 147

  Authors: Anas M., Mohamed M., Muneer J., Inas A., Mohamad Bassam, Thai H.

• The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer

  Citation: 147

  Authors: Roberto, Chiara, Emilio, Mario, Emanuela, Davide, Alessandro, Antonio Benito, Salvatore, Matteo, Renzo, Walter, Giampaolo

• Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States

  Citation: 138

  Authors: Daniel J., Oliver, Kurt, Fred, Bertrand, Ján, Xiaolong, Krishna, Cora N., Celestia S.

• A Phase II Study of Depsipeptide in Refractory Metastatic Renal Cell Cancer

  Citation: 128

  Authors: Walter M., Kim, Sandy, William, John A.

• Phase I Study Combining Treatment with Temsirolimus and Sunitinib Malate in Patients with Advanced Renal Cell Carcinoma

  Citation: 124

  Authors: Premal H., Peggy L., Rafael E., Robert J.

• Expression of microRNAs in the Urine of Patients With Bladder Cancer

  Citation: 123

  Authors: Gang, Eddie Shu-Yin, Bonnie Ching-Ha, Philip Kam-Tao, Sidney Kam-Hung, Cheuk-Chun, Chi-Fai

• Comparison of Circulating MicroRNA 141 to Circulating Tumor Cells, Lactate Dehydrogenase, and Prostate-Specific Antigen for Determining Treatment Response in Patients With Metastatic Prostate Cancer

  Citation: 114

  Authors: Jason C., Louis M., Oscar B., James T., Nicholas J., David C.

---